PDF(Pubmed)
Abstract：
BACKGROUND: Sebaceous gland carcinoma (SGC) of the eyelid is an aggressive tumour with the ability to metastasise and an increased morbidity. Controversies regarding the epidemiology of this malignant eyelid tumour is widespread in the scientific literature. Western reports repeatedly describes eyelid SGC as a rare occurring tumour in general, accounting for 1%-3% of all eyelid tumours, however studies from Asia have uncovered a higher frequency of eyelid SGC including 54% of all eyelid tumours in Japan, and 43%-56% in India. We wish to retrieve observational data of eyelid SGC prevalence in proportion to total eyelid tumours, from pathological studies published worldwide to resolve this controversy.
METHODS: We will search Ovid Medline, EMBASE, Cochrane Central Register of Controlled Trials, Scopus and Google Scholar to identify published reports on eyelid SGC prevalence proportions, aiming to clarify the incidence of the tumour. We will include observational clinicopathological studies reporting prevalence with confirmed histopathology. No limitations on publication date or language will be applied. Data from the individual studies and study quality will be extracted by two individual reviewers. Study quality will be assessed using the JBI Critical Appraisal Instrument for Studies Reporting Prevalence Data. Raw proportions will be transformed and pooled using a random effects model for meta-analysis. And subgroup analysis according to geography will be performed. If data are deemed unsuitable for a meta-analysis, a narrative synthesis will be presented. We will judge the certainty of evidence and present whether this has an overall effect on the results. The results may shed light on a long-standing academic disparity of the scientific literature.
BACKGROUND: This systematic review does not require ethical approval. The results of this proposed review will be the subject to a publication in an international peer-reviewed journal within the ophthalmic or pathological specialty.
UNASSIGNED: CRD42023487141.
METHODS: We will search Ovid Medline, EMBASE, Cochrane Central Register of Controlled Trials, Scopus and Google Scholar to identify published reports on eyelid SGC prevalence proportions, aiming to clarify the incidence of the tumour. We will include observational clinicopathological studies reporting prevalence with confirmed histopathology. No limitations on publication date or language will be applied. Data from the individual studies and study quality will be extracted by two individual reviewers. Study quality will be assessed using the JBI Critical Appraisal Instrument for Studies Reporting Prevalence Data. Raw proportions will be transformed and pooled using a random effects model for meta-analysis. And subgroup analysis according to geography will be performed. If data are deemed unsuitable for a meta-analysis, a narrative synthesis will be presented. We will judge the certainty of evidence and present whether this has an overall effect on the results. The results may shed light on a long-standing academic disparity of the scientific literature.
BACKGROUND: This systematic review does not require ethical approval. The results of this proposed review will be the subject to a publication in an international peer-reviewed journal within the ophthalmic or pathological specialty.
UNASSIGNED: CRD42023487141.
摘要：
背景：眼睑皮脂腺癌（SGC）是一种侵袭性肿瘤，具有转移能力和增加的发病率。关于这种恶性眼睑肿瘤的流行病学的争议在科学文献中很普遍。西方报道反复将眼睑SGC描述为一种罕见的肿瘤，占所有眼睑肿瘤的1%-3%，然而，来自亚洲的研究发现眼睑SGC的频率更高，包括日本54%的眼睑肿瘤，印度占43%-56%。我们希望检索眼睑SGC患病率与总眼睑肿瘤成比例的观察数据，从世界各地发表的病理学研究中解决了这一争议。
方法：我们将搜索OvidMedline，EMBASE,Cochrane中央控制试验登记册,Scopus和谷歌学者确定已发表的关于眼睑SGC患病率比例的报告，旨在澄清肿瘤的发病率。我们将包括观察性临床病理研究，报告患病率并确认组织病理学。对出版日期或语言没有限制。来自个体研究和研究质量的数据将由两名个体审阅者提取。研究质量将使用JBI关键评估仪器评估研究报告患病率数据。将使用用于荟萃分析的随机效应模型来转换和汇集原始比例。并根据地理位置进行亚组分析。如果数据被认为不适合进行荟萃分析，将呈现叙事综合。我们将判断证据的确定性，并提出这是否对结果有总体影响。结果可能会揭示科学文献的长期学术差异。
背景：本系统评价不需要道德批准。这项拟议审查的结果将成为眼科或病理专业内国际同行评审期刊上出版物的主题。
■CRD42023487141。
方法：我们将搜索OvidMedline，EMBASE,Cochrane中央控制试验登记册,Scopus和谷歌学者确定已发表的关于眼睑SGC患病率比例的报告，旨在澄清肿瘤的发病率。我们将包括观察性临床病理研究，报告患病率并确认组织病理学。对出版日期或语言没有限制。来自个体研究和研究质量的数据将由两名个体审阅者提取。研究质量将使用JBI关键评估仪器评估研究报告患病率数据。将使用用于荟萃分析的随机效应模型来转换和汇集原始比例。并根据地理位置进行亚组分析。如果数据被认为不适合进行荟萃分析，将呈现叙事综合。我们将判断证据的确定性，并提出这是否对结果有总体影响。结果可能会揭示科学文献的长期学术差异。
背景：本系统评价不需要道德批准。这项拟议审查的结果将成为眼科或病理专业内国际同行评审期刊上出版物的主题。
■CRD42023487141。
